BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 38354702)

  • 1. The B7:CD28 family and friends: Unraveling coinhibitory interactions.
    Burke KP; Chaudhri A; Freeman GJ; Sharpe AH
    Immunity; 2024 Feb; 57(2):223-244. PubMed ID: 38354702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.
    Schildberg FA; Klein SR; Freeman GJ; Sharpe AH
    Immunity; 2016 May; 44(5):955-72. PubMed ID: 27192563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD28/B7 costimulation: a review.
    Greenfield EA; Nguyen KA; Kuchroo VK
    Crit Rev Immunol; 1998; 18(5):389-418. PubMed ID: 9784967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CD28-B7 Family of Co-signaling Molecules.
    Nagai S; Azuma M
    Adv Exp Med Biol; 2019; 1189():25-51. PubMed ID: 31758530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
    Fife BT; Bluestone JA
    Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The B7-CD28/CTLA-4 costimulatory pathways in autoimmune disease of the central nervous system.
    Anderson DE; Sharpe AH; Hafler DA
    Curr Opin Immunol; 1999 Dec; 11(6):677-83. PubMed ID: 10631554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion.
    Wu Y; Guo Y; Huang A; Zheng P; Liu Y
    J Exp Med; 1997 Apr; 185(7):1327-35. PubMed ID: 9104819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD28 function: a balance of costimulatory and regulatory signals.
    Bour-Jordan H; Blueston JA
    J Clin Immunol; 2002 Jan; 22(1):1-7. PubMed ID: 11958588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The B7 family revisited.
    Greenwald RJ; Freeman GJ; Sharpe AH
    Annu Rev Immunol; 2005; 23():515-48. PubMed ID: 15771580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of B7-CD28 costimulation in urologic malignancies.
    Thompson RH; Kwon ED; Allison JP
    Immunotherapy; 2009 Jan; 1(1):129-39. PubMed ID: 20445772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.
    Kleinpeter P; Remy-Ziller C; Winter E; Gantzer M; Nourtier V; Kempf J; Hortelano J; Schmitt D; Schultz H; Geist M; Brua C; Hoffmann C; Schlesinger Y; Villeval D; Thioudellet C; Erbs P; Foloppe J; Silvestre N; Fend L; Quemeneur E; Marchand JB
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30918073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies.
    Pulanco MC; Madsen AT; Tanwar A; Corrigan DT; Zang X
    Cell Mol Immunol; 2023 Jul; 20(7):694-713. PubMed ID: 37069229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?
    van Gool SW; Barcy S; Devos S; Vandenberghe P; Ceuppens JL; Thielemans K; de Boer M
    Res Immunol; 1995; 146(3):183-96. PubMed ID: 8525052
    [No Abstract]   [Full Text] [Related]  

  • 15. The CD28-B7 costimulatory pathway and its role in autoimmune disease.
    Daikh D; Wofsy D; Imboden JB
    J Leukoc Biol; 1997 Aug; 62(2):156-62. PubMed ID: 9261329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revealing the atomistic details behind the binding of B7-1 to CD28 and CTLA-4: A comprehensive protein-protein modelling study.
    Ganesan A; Moon TC; Barakat KH
    Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2764-2778. PubMed ID: 30251665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy.
    Li Y; Lv C; Yu Y; Wu B; Zhang Y; Lang Q; Liang Z; Zhong C; Shi Y; Han S; Xu F; Tian Y
    J Adv Res; 2023 May; 47():137-150. PubMed ID: 35933091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo.
    Bai XF; Liu J; May KF; Guo Y; Zheng P; Liu Y
    Blood; 2002 Apr; 99(8):2880-9. PubMed ID: 11929778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CTLA-4 and T cell activation.
    Oosterwegel MA; Greenwald RJ; Mandelbrot DA; Lorsbach RB; Sharpe AH
    Curr Opin Immunol; 1999 Jun; 11(3):294-300. PubMed ID: 10375557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CD28/CTLA-4-B7 signaling pathway is involved in both allergic sensitization and tolerance induction to orally administered peanut proteins.
    van Wijk F; Nierkens S; de Jong W; Wehrens EJ; Boon L; van Kooten P; Knippels LM; Pieters R
    J Immunol; 2007 Jun; 178(11):6894-900. PubMed ID: 17513738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.